Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: Relationship with erythropoietin requirements

Meur, Yann Le; Lorgeot, Valérie; Comte, Lydie; Szelag, Jean-Christophe; Aldigier, Jean-Claude; Leroux-Robert, C.; Perreten, Vincent

doi:10.1053/ajkd.2001.26839

Cited by 69 publications

(50 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18) We reported previously that plasma AcSDKP-IS levels in patients with ESRD before kidney transplantation were higher than those of healthy subjects (1.29± 0.56 vs. 0.29± 0.07 pmol/ mL), 21) which was consistent with past reports of elevated plasma AcSDKP levels in patients with chronic renal failure. 18,19) Plasma AcSDKP-IS level decreased significantly from day 3 after kidney transplantation compared to before kidney transplantation. The degrees of decrease in plasma AcSDKP-IS level were not different between living and cadaveric kidney transplant recipients (data not shown).…”

Section: )supporting

confidence: 90%

“…Increases in plasma AcSDKP level have been reported in patients with various diseases, such as chronic renal failure, 18,19) chronic heart failure 24) and hematologic malignancy.…”

Section: Discussionmentioning

confidence: 99%

“…16,17) To the best of our knowledge, only two studies have examined plasma AcSDKP levels in patients with end stage renal disease (ESRD). 18,19) Le Meur et al 18) found that plasma AcSDKP level is elevated in hemodialysis patients and that residual renal function independently predicts plasma AcSDKP level. Inoue et al 19) also reported elevated plasma AcSDKP level in hemodialysis patients.…”

Section: Significant Decrease In Plasma N-acetyl-seryl-aspartyl-lysylmentioning

confidence: 99%

“…[3][4][5] Van der Meer et al 24) have reported that plasma AcSDKP level is significantly higher in the anemic chronic heart failure patients compared with nonanemic chronic heart failure patients and that plasma AcSDKP correlates negatively with proliferation of erythropoietic progenitor cells. Le Meur et al 18) have reported a relation between AcSDKP level and the weekly dose of recombinant human erythropoietin for the treatment of renal anemia. Their findings suggest an inhibitory role of AcSDKP on hematopoiesis.…”

Section: )mentioning

confidence: 99%

See 3 more Smart Citations

Significant Decrease in Plasma <i>N</i>-Acetyl-seryl-aspartyl-lysyl-proline Level in Patients with End Stage Renal Disease after Kidney Transplantation

Suzuki

Katagiri

Sato

et al. 2014

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

N-Acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an endogenous peptide released from its precursor (thymosin-β4) by prolyl oligopeptidase. AcSDKP is a natural inhibitor of pluripotent hematopoietic stem cell proliferation and is normally found in human plasma. AcSDKP has been shown to be a potent angiogenic factor and to suppress renal fibroblast proliferation. Impairment of renal function has been suggested to have a significant impact on plasma AcSDKP level. The aim of this study was to assess whether improvement of renal function after kidney transplantation has an impact on plasma AcSDKP-like immunoreactive substance (IS) level. Fourteen patients with end stage renal disease (ESRD) who were scheduled to undergo the first kidney allograft transplantation were enrolled. Plasma AcSDKP-IS levels were measured before and 3, 7, 10, 14, 21, 30, 60 and 90 d after kidney transplantation. Plasma AcSDKP-IS level decreased significantly from day 3 after kidney transplantation compared to before kidney transplantation. Creatinine clearance increased significantly from day 7 after kidney transplantation. A significant negative correlation was observed between creatinine clearance and plasma AcSDKP-IS level from before transplantation to 90 d after kidney transplantation. Stepwise multiple regression analysis identified creatinine clearance as the only significant independent factor associated with plasma AcSDKP-IS levels. These results suggest that recovery of kidney function after kidney transplantation may lead to a decrease in plasma AcSDKP level in patients with ESRD, and that plasma AcSDKP level may depend largely on renal function.

show abstract

Section: )supporting

confidence: 90%

“…Increases in plasma AcSDKP level have been reported in patients with various diseases, such as chronic renal failure, 18,19) chronic heart failure 24) and hematologic malignancy.…”

Section: Discussionmentioning

confidence: 99%

Section: Significant Decrease In Plasma N-acetyl-seryl-aspartyl-lysylmentioning

confidence: 99%

Section: )mentioning

confidence: 99%

See 2 more Smart Citations

Significant Decrease in Plasma <i>N</i>-Acetyl-seryl-aspartyl-lysyl-proline Level in Patients with End Stage Renal Disease after Kidney Transplantation

Suzuki

Katagiri

Sato

et al. 2014

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…29 Comte et al 30 found that besides degradation by ACE, Ac-SDKP is partially eliminated in the kidney. We found that GFRc was lower in anemic CHF patients compared with nonanemic CHF patients, which might have influenced Ac-SDKP levels.…”

Section: Van Der Meer Et Al Serum Of Chf Patients Inhibits Erythropoimentioning

confidence: 99%

Levels of Hematopoiesis Inhibitor N -Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure

et al. 2005

View full text Add to dashboard Cite

Background— Anemia is common in patients with chronic heart failure (CHF) and is associated with a poor prognosis. However, only a minority of patients with CHF have impaired renal function or underlying hematinic deficiencies. It has been shown that inhibition of the renin-angiotensin system is associated with the development of anemia. The aim of the present study was to determine possible mechanisms linking anemia to renin-angiotensin system activity in CHF patients. Methods and Results— We initially evaluated 98 patients with advanced stable CHF who were treated with ACE inhibitors (left ventricular ejection fraction, 28±1%; age, 69±1 years; 80% male), 10 of whom had an unexplained anemia (normal hematinics and no renal failure). These 10 anemic patients were matched with 10 nonanemic patients in terms of age and left ventricular ejection fraction. Serum ACE activity was 73% lower in anemic CHF patients compared with nonanemic CHF patients ( P =0.018). Moreover, serum of these patients inhibited in vitro the proliferation of bone marrow–derived erythropoietic progenitor cells of healthy donors by 17% ( P =0.003). Levels of the hematopoiesis inhibitor N -acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), which is almost exclusively degraded by ACE, were significantly higher in anemic CHF patients and were clearly correlated to erythroid progenitor cell proliferation ( r =−0.64, P =0.001). Conclusions— Serum ACE activity is markedly lower in anemic CHF patients, and serum of these patients inhibits hematopoiesis. The clear correlation between Ac-SDKP and proliferation of erythroid progenitor cells suggests an inhibitory role of Ac-SDKP on hematopoiesis in CHF patients, which may explain the observed anemia in patients treated with ACE inhibitors.

show abstract

Longitudinal Follow-up and Outcomes Among a Population With Chronic Kidney Disease in a Large Managed Care Organization

Keith¹,

Nichols²,

Gullion³

et al. 2004

Arch Intern Med

1,474

911

View full text Add to dashboard Cite

show abstract

Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: Relationship with erythropoietin requirements

Cited by 69 publications

References 29 publications

Significant Decrease in Plasma <i>N</i>-Acetyl-seryl-aspartyl-lysyl-proline Level in Patients with End Stage Renal Disease after Kidney Transplantation

Significant Decrease in Plasma <i>N</i>-Acetyl-seryl-aspartyl-lysyl-proline Level in Patients with End Stage Renal Disease after Kidney Transplantation

Levels of Hematopoiesis Inhibitor N -Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure

Longitudinal Follow-up and Outcomes Among a Population With Chronic Kidney Disease in a Large Managed Care Organization

Contact Info

Product

Resources

About